Cambridge, Massachusetts-based Moderna, Inc. (MRNA), a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases. The company is valued at $79.9 billion by market cap. The pharmaceutical and biotechnology company is expected to announce its fiscal third-quarter earnings for 2026 before the market opens on Friday, Nov. 6.
Ahead of the event, analysts expect Moderna to report a loss of $1.10 per share on a diluted basis, down 115.7% from $0.51 per share in the year-ago quarter. The company has consistently surpassed or met Wall Street’s bottom-line estimates in its last four quarterly reports.